We are live on ! Find out more
LAB icon

Standard BioTools
LAB

141 hedge funds and large institutions have $543M invested in Standard BioTools in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

13% more capital invested

Capital invested by funds: $480M → $543M (+$62.5M)

2.53% more ownership

Funds ownership: 73.23% → 75.76% (+2.5%)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

2% less funds holding

Funds holding: 144 → 141 (-3)

11% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 45

21% less call options, than puts

Call options by funds: $72K | Put options by funds: $91K

Holders
141
Holders Change
-3
Holders Change %
-2.08%
% of All Funds
2.02%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
21
Increased
40
Reduced
45
Closed
22
Calls
$72K
Puts
$91K
Net Calls
-$19K
Net Calls Change
-$1.17M

Top Buyers

1
CC
Casdin Capital
New York
+$14.3M
2
HBWM
Hollow Brook Wealth Management
New York
+$10.8M
3
Morgan Stanley
Morgan Stanley
New York
+$4.53M
4
Northern Trust
Northern Trust
Illinois
+$3.19M
5
Charles Schwab
Charles Schwab
California
+$3.13M

Top Sellers

1
AIM
ARK Investment Management
Florida
-$7.3M
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$2.14M
3
NAMA
Nikko Asset Management Americas
New York
-$2.09M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$2.08M
5
ICM
Invenomic Capital Management
Massachusetts
-$1.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIM
26
Needham Investment Management
New York
$1.51M -$392K -200,000 -20%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.46M -$442K -225,515 -23%
RA
28
Royce & Associates
New York
$1.19M +$608K +310,321 +102%
PCMI
29
Paradigm Capital Management Inc
New York
$1.06M – – –
Swiss National Bank
30
Swiss National Bank
Switzerland
$907K -$37K -18,900 -4%
IP
31
Intellectus Partners
California
$810K – – –
TCM
32
Tang Capital Management
California
$787K +$799K +407,755 New
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$736K -$50.9K -25,978 -6%
Dimensional Fund Advisors
34
Dimensional Fund Advisors
Texas
$641K -$58.8K -30,004 -8%
AllianceBernstein
35
AllianceBernstein
Tennessee
$609K – – –
Two Sigma Investments
36
Two Sigma Investments
New York
$606K -$175K -89,288 -22%
JJ
37
Johnson & Johnson
New Jersey
$602K – – –
UBS AM
38
UBS AM
Illinois
$592K -$148K -75,617 -20%
CAC
39
Cowen and Company
New York
$530K – – –
UBS Group
40
UBS Group
Switzerland
$489K +$152K +77,769 +44%
Legal & General Group
41
Legal & General Group
United Kingdom
$477K -$493 -252 -0.1%
DCM
42
Driehaus Capital Management
Illinois
$456K – – –
Squarepoint
43
Squarepoint
New York
$456K -$135K -69,120 -23%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$447K -$29K -14,785 -6%
Citigroup
45
Citigroup
New York
$445K +$303K +154,691 +204%
Renaissance Technologies
46
Renaissance Technologies
New York
$388K -$1.57M -803,558 -80%
Bank of America
47
Bank of America
North Carolina
$358K -$142K -72,434 -28%
American Century Companies
48
American Century Companies
Missouri
$354K +$168K +85,983 +88%
Jane Street
49
Jane Street
New York
$351K -$118K -60,340 -25%
Deutsche Bank
50
Deutsche Bank
Germany
$325K +$83.6K +42,668 +34%
1
2
3 4 5

LAB Hedge Fund Activity: Q3 2024 in Review

141 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2024, worth a combined $543M — up 13% from $480M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of LAB and 21 opened new positions — a net loss of 1 holder — while 45 trimmed existing stakes and 40 added.

The largest buyer was Casdin Capital, adding an estimated $14.3M. The largest seller was ARK Investment Management, cutting an estimated $7.3M.

  • 141 institutional investors held Standard BioTools (LAB) as of Q3 2024, down from 144 in Q2 2024.
  • Funds reported $543M of Standard BioTools stock for Q3 2024, up 13% quarter-over-quarter.
  • 21 funds opened new Standard BioTools positions in Q3 2024 and 22 closed out, a net change of -1 holder.
  • The largest Standard BioTools buyer in Q3 2024 was Casdin Capital, an estimated $14.3M added.
  • The largest Standard BioTools seller in Q3 2024 was ARK Investment Management, an estimated $7.3M sold.

Based on aggregated 13F filings for Q3 2024.